| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/11/2009 | US20090149523 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases |
| 06/11/2009 | US20090149519 Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments |
| 06/11/2009 | US20090149513 Compositions of an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy |
| 06/11/2009 | US20090149508 Process for the preparation of substituted phenyl ether compounds |
| 06/11/2009 | US20090149503 New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes |
| 06/11/2009 | US20090149492 3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-7,8-dihydro-1,6-naphthyridin-5(6H)-one, used as antidiabetic agents |
| 06/11/2009 | US20090149487 4,5-diphenyl-pyrimidinylamino substituted carboxylic acids, method for the production and use thereof as medicaments |
| 06/11/2009 | US20090149486 4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments |
| 06/11/2009 | US20090149485 Pyrimidinediones as tyrosine kinase inhibitors |
| 06/11/2009 | US20090149483 Bicyclic pyrrole derivatives |
| 06/11/2009 | US20090149477 use for lowering blood glucose, treating diabetes, or increasing insulin release; 7-(4,5-Diphenylpyrimidin-2-yl)-6-heptynoic Acid |
| 06/11/2009 | US20090149463 Therapeutic agents |
| 06/11/2009 | US20090149460 New Compounds |
| 06/11/2009 | US20090149451 Pharmaceutical formulations of potassium atp channel openers and uses thereof |
| 06/11/2009 | US20090149445 Tricyclic steroid hormone nuclear receptor modulators |
| 06/11/2009 | US20090149402 Pharmaceutical composition for treating cancer or diabetes |
| 06/11/2009 | US20090149398 6,11-3c-bicyclic 8a-azalide derivatives |
| 06/11/2009 | US20090149387 Use of GLP-1 Peptides |
| 06/11/2009 | US20090149382 Modulation of lipid rafts |
| 06/11/2009 | US20090149378 Glp-1 analogues |
| 06/11/2009 | US20090148546 Methods and compounds fo rthe treatment of obesity and obesity-related disorders |
| 06/11/2009 | US20090148436 Antibody to gdf8 and uses thereof |
| 06/11/2009 | US20090148430 Human obesity susceptibilty gene encoding potassium ion channels and uses thereof |
| 06/11/2009 | US20090148412 lowering plasma cholesterol level in a subject by administering a preparation comprising an isolated membrane fraction separated from cytoplasmic material, the membrane fraction made from bacteria of Rhodospirillum spp. and/or Phaeospirillum spp |
| 06/11/2009 | US20090148401 Methods and compositions for needleless delivery of binding partners |
| 06/11/2009 | US20090145432 Medicament delivery assembly |
| 06/11/2009 | CA2715527A1 New compounds iv |
| 06/11/2009 | CA2707671A1 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases |
| 06/11/2009 | CA2707669A1 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases |
| 06/11/2009 | CA2707667A1 Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
| 06/11/2009 | CA2707663A1 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| 06/11/2009 | CA2707656A1 Probiotic bacteria and regulation of fat storage |
| 06/11/2009 | CA2707651A1 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
| 06/11/2009 | CA2707555A1 Piperazines as anti-obesity agents |
| 06/11/2009 | CA2707549A1 Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism |
| 06/11/2009 | CA2707248A1 New compounds ii |
| 06/11/2009 | CA2706933A1 Nanoparticles of therapeutic agents having low water solubility |
| 06/11/2009 | CA2706821A1 Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome |
| 06/11/2009 | CA2706632A1 Substituted 2-naphthoic acids as antagonists of gpr105 activity |
| 06/11/2009 | CA2704266A1 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| 06/10/2009 | EP2067863A2 Methods and compositions for diseases associated with amyloidosis |
| 06/10/2009 | EP2067781A1 Agent for improving insulin resistance |
| 06/10/2009 | EP2067488A1 Albumin fusion proteins |
| 06/10/2009 | EP2067481A1 Therapeutic use of desacyl ghrelin |
| 06/10/2009 | EP2067480A1 Musclin receptor and use thereof |
| 06/10/2009 | EP2067479A1 A hypolipidemic composition and its use |
| 06/10/2009 | EP2067478A1 Agent for prevention or treatment of blood glucose level elevation |
| 06/10/2009 | EP2066668A1 Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
| 06/10/2009 | EP2066664A1 Heterocyclic organic compounds |
| 06/10/2009 | EP2066663A1 Heterocyclic fxr binding compounds |
| 06/10/2009 | EP2066644A2 Salts of rosuvastatin and processes for their preparation |
| 06/10/2009 | EP2066635A2 2-phenoxy nicotine acid derivative and use thereof |
| 06/10/2009 | EP2066409A2 Use of quinoa extract as cosmetic and pharmaceutic slimming agent and/or as an agent preventing the formation of new fats in the human body |
| 06/10/2009 | EP2066337A2 Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| 06/10/2009 | EP2066324A2 Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
| 06/10/2009 | EP2066186A1 Green tea extract, especially for use as a functional food item, food supplement or corresponding ingredient, the use thereof and method for producing said green tea extract |
| 06/10/2009 | EP2066174A2 Compositions containing alpha-1-antitrypsin and methods for use |
| 06/10/2009 | EP1474385B1 Urea linker derivatives for use as ppar modulators |
| 06/10/2009 | EP1319003B1 Xanthine phosphodiesterase v inhibitors |
| 06/10/2009 | EP1289573B1 A medicinal aerosol antidiabetics formulation |
| 06/10/2009 | EP1115421B1 Use of glp-1 or analogs in treatment of stroke |
| 06/10/2009 | CN101450934A Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| 06/10/2009 | CN100497628C Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 06/10/2009 | CN100497610C Polypeptides encoded by human lipase-like gene and composition, and methods of utilizing same |
| 06/10/2009 | CN100497608C Human cholesteryl ester synthetase-2c and its coding sequence |
| 06/10/2009 | CN100497598C Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 06/10/2009 | CN100497388C Antibody selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and use thereof |
| 06/10/2009 | CN100497362C Aminoglucose acid, chromium complex with its derivative and preparation and use thereof |
| 06/10/2009 | CN100497340C Condensed purine derivatives as A1 adenosine receptor antagonists |
| 06/10/2009 | CN100497334C Indole derivatives useful as histamine h3 antagonists |
| 06/10/2009 | CN100497323C New heterocyclic oxime compounds, preparing process and medical composition thereof |
| 06/10/2009 | CN100497314C Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
| 06/10/2009 | CN100497313C New isoquinoline compounds, their preparation method and medicine composition containing them |
| 06/10/2009 | CN100496563C Combination of natural products for curing hyperlipemia, atherosclerosis and relevant disease |
| 06/10/2009 | CN100496561C Medicine for improving sugar tolerance and treating diabetes and its preparation process |
| 06/10/2009 | CN100496536C Alpha-glucosidase activity inhibitor |
| 06/10/2009 | CN100496533C Medicine for treating diabetes |
| 06/10/2009 | CN100496525C Technique of extracting acitve ingredient from roots, stems and leaves from artichoke and application |
| 06/10/2009 | CN100496501C Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist |
| 06/10/2009 | CN100496495C Remedies and/or preventives for diabetic ischemic heart diseases |
| 06/10/2009 | CN100496298C Process for producing liquid formulation containing raw yeast and liquid formulation |
| 06/10/2009 | CN100496258C Composition for treating diabetes and preparing method thereof |
| 06/09/2009 | US7544859 for introducing DNA into organisms which produce large amounts of oils; genetic engineering; for animal feed, foods, cosmetics and pharmaceuticals; kits |
| 06/09/2009 | US7544839 N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide; nervous system disorders; melatoninergic system disorders; industrial synthesis |
| 06/09/2009 | US7544835 Carboxylic acid derivative and salt thereof |
| 06/09/2009 | US7544812 For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus |
| 06/09/2009 | US7544708 To treat diseases of respiratory, urinary and gastrointestinal systems; highly selective; significant potency; (2R,2S)(1 alpha ,5 alpha ,6 alpha )-N-{-[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo[3.1.0]hex-6-yl-methyl}-2-hydroxy-2-cyclopentyl-2-phenylacetamide |
| 06/09/2009 | US7544690 MCH receptor antagonists |
| 06/09/2009 | US7544689 (2S3R)-3-{9-Isopropyl-6-[(pyridin-2-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative; cancer, leukemia, psoriasis; cyclin-dependent kinase (CDK) inhibitors |
| 06/09/2009 | US7544687 (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-m-tolyl-piperazin-1-yl)-propionic acid; hyperglycemia, dyslipidemia, type II diabetes mellitus; (2S)-2-[4-(4-nitro-benzenesulfonyl)-piperazin-1-yl]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid; |
| 06/09/2009 | US7544684 Hydrazono-malonitriles |
| 06/09/2009 | US7544669 Polynucleotide therapy |
| 06/09/2009 | US7544510 Stem cells of the islets of Langerhans and their use in treating diabetes mellitus |
| 06/09/2009 | US7544480 drug screening an antagonist which inhibits hydroxylation of hypoxia inducible factor or an agonist which promotes hydroxylation of hypoxia inducible factor; hydroxylation of asparagine; antitumor agent; use for radiotherapy or chemotherapy |
| 06/09/2009 | US7544357 Administering an interferon antagonist and a FMS-like tyrosine kinase 3 ("Flt3") ligand antagonist, such as an anti-IFN-alpha antibody; in vitro assay for determining risk for developing an autoimmune disease |
| 06/09/2009 | CA2410706C Composition and applicator for topical substance delivery |
| 06/09/2009 | CA2355720C New substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines |
| 06/09/2009 | CA2350659C Pharmaceutical composition for modified release insulin sensitiser |
| 06/09/2009 | CA2337350C Polyhydroxyalkylpyrazine derivatives, their preparation, and pharmaceutical compositions containing them |
| 06/09/2009 | CA2326198C Cosolvent formulations |